QIBA fMRI Biomarker Committee (BC) Call
Wednesday, March 22, 2017 at 11 AM CT
Call Summary

In attendance
Ted DeYoe, PhD (Co-Chair) Feroze Mohamed, PhD David Soltyzik, PhD
Cathy Elsinger, PhD Nancy Obuchowski, PhD James Voyvodic, PhD
Andrew Kalnin, MD

RSNA
Joe Koudelik
Nancy Obuchowski, PhD Susan Weinmann

Review of Previous Call Summary
• The 3.08.2017 call summary was approved as presented

Announcements
• Status of future NIBIB funding (Dr. Elsinger)
  o Due to uncertain NIH funding and other NIBIB funding obligations, NIBIB announced that the QIBA Contract will not be re-competited
  o No funding will be available for new QIBA projects
  o RSNA remains supportive of the QIBA efforts and plans to continue support the administration of calls and scaled-down f2f meetings
  o The revitalized Sustainability Task Force to address alternative funding strategies under the leadership of Dr. Annette Schmid
  o Those who have ideas on funding options or collaborations to explore were encouraged to contact MR CC Chairs

• QIBA Annual Meeting
  o The 2017 meeting to proceed as planned
  o The 2018 QIBA Annual Meeting will likely be held in May, near RSNA Headquarters in Oak Brook, Illinois
    • Details regarding the size and scope of the meeting is yet to be determined

fMRI Profile v1.0 draft (All)
• To support concurrent access and editing, the fMRI Profile v1.0 is on Google docs at:
  https://docs.google.com/document/d/1M8XywlKVYSi9_SXfmvkPzVdnunVTXHwc3CdnqFTrsCw/edit?usp=sharing
• Vote-to-release e-ballot, sent out to eight fMRI BC eligible voters, closed with 6 “Yes” and 1 “No”, thus approving Profile release
• Next step is the MR CC e-ballot vote-to-release process
• 4.1 Assessment Procedure: fMRI center-of-mass reproducibility (Claim)
  o Dr. Elsinger to coordinate with Drs. Obuchowski, Voyvodic, et al. to organize data and the required specification of the Claim measurement, then modify section 4.1 and Appendix G according to “Actor”
  o Need to clarify the “Actor” roles better, e.g. who is responsible for individual assessment procedures
    • Manufacturers, Technicians, and imaging sites will be Actors and have specific assessment criteria
Discussion on arriving at 3.84 in the procedure step: “Compute the mean variance over all the subjects. Compare the result with the Profile Claim. A mean variance ≤3.84 demonstrates conformance with this requirement.”

A collection of DROs is being provided for users to test that equipment meets fMRI Profile QA requirements.

3.7.2 Specification Table

- The discussion of head motion as a source of variation was revisited
- Differences between random and task-correlated head motion were discussed
- DRO head motion data to be reviewed in Appendix H
- Dr. Soltysik’s measurements regarding pitch, yaw and roll to be cited in Profile after his paper is published

Methodology for assessing head motion to be added; Profile users to be provided a well-defined way to compute and use the data; if this is not possible, then head motion detail to be removed from Profile

Next calls:

- QIBA fMRI Bias TF call - Tuesday, April 11 at 10am CT
- QIBA fMRI Biomarker Committee call – Wednesday, April 5 at 11am CT